Table 2 Patient characteristics
Characteristics | Total (n = 192) | Intervention group (n = 95) | Control group (n = 97) | Standardized difference |
|---|---|---|---|---|
Age, years | 65 (58–72) | 65 (59–73) | 66 (58–71) | 0.08 |
Male sex | 99 (51.6) | 51 (53.7) | 48 (49.5) | 0.08 |
Cardiovascular risk factors | ||||
 BMI, kg/m2 | 27.2 (4.8) | 27.9 (4.6) | 26.4 (4.9) | -0.31 |
 Predisposed to CVD | 44 (22.9) | 18 (18.9) | 26 (26.8) | 0.23 |
 Known EF < 45% | 3 (1.6) | 1 (1.1) | 2 (2.1) | N/A |
 Aspirin treatment | 19 (9.9) | 11 (11.6) | 8 (8.2) | 0.11 |
 Diabetes | 31 (16.1) | 13 (13.7) | 18 (18.6) | 0.13 |
 Hypertension | 89 (46.4) | 47 (49.5) | 42 (43.3) | 0.12 |
 Hypercholesterolemia | 56 (29.2) | 25 (26.3) | 31 (32.0) | 0.12 |
 Active smoker | 31 (16.1) | 14 (14.7) | 17 (17.5) | 0.08 |
Cancer characteristics | ||||
 Site | ||||
  Colon | 93 (48.4) | 43 (45.3) | 50 (51.5) | 0.28 |
  Rectum | 41 (21.4) | 24 (25.3) | 17 (17.5) |  |
  Pancreas | 19 (9.9) | 7 (7.4) | 12 (12.4) |  |
  Breast | 36 (18.8) | 20 (21.1) | 16 (16.5) |  |
  Appendix | 3 (1.6) | 1 (1.1) | 2 (2.1) |  |
 Stage | ||||
  I | 5 (2.6) | 1 (1.1) | 4 (4.1) | 0.39 |
  II | 16 (8.3) | 9 (9.5) | 7 (7.2) |  |
  III | 74 (38.5) | 33 (34.7) | 41 (42.3) |  |
  IV | 91 (47.4) | 47 (49.5) | 44 (45.4) |  |
  Missing | 6 (3.1) | 5 (5.3) | 1 (1.0) |  |
Treatment indication | ||||
  Adjuvant | 97 (50.5) | 48 (50.5) | 49 (50.5) | 0.02 |
  Neo-adjuvant | 41 (21.4) | 20 (21.1) | 21 (21.6) |  |
  Palliation | 54 (28.1) | 27 (28.4) | 27 (27.8) |  |
Treatment regimen | ||||
 Capecitabine monotherapy | 79 (41.1) | 45 (47.4) | 34 (35.1) | 0.25 |
 Capecitabine in combinationa | 80 (41.7) | 35 (36.8) | 45 (46.4) | |
 5-FU in combinationb | 33 (17.2) | 15 (15.8) | 18 (18.6) | |
Concomitant radiation | 6 (3.1) | 4 (4.2) | 2 (2.1) | 0.12 |
Previous anthracycline treatment | 29 (15.1) | 15 (15.8) | 14 (14.4) | 0.15 |
Previous chest radiation | 31 (16.1) | 16 (17.0) | 15 (15.5) | 0.15 |